Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

LifeSprout, Inc. Appoints Michael Kranda as CEO and Director

LifeSprout, Inc., a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced the appointment of Michael Kranda as CEO and member of the board of directors.

"We're pleased to have attracted an executive of Michael's caliber to lead LifeSprout at this pivotal time for the company as we proceed to leverage the full potential of our regenerative cell therapy platform," said Sashank Reddy, M.D., Ph.D., co-founder of LifeSprout.

"I welcome the opportunity to lead the LifeSprout team, and collaborate with the thought leaders in tissue engineering, nano biotechnology, and materials science from Johns Hopkins to establish a new standard of bio stimulatory products for cell therapy applications," said Kranda, LifeSprout, Inc. CEO.

Kranda comes to LifeSprout from gene therapy pioneer AskBio, where he served as SVP of Alliance Management and guided their central nervous system (CNS) gene therapy portfolio. Prior to joining AskBio, Kranda served as Senior Director of Business Development for the Allen Institute where he led efforts to establish partnerships initiatives in gene and cell therapy, and 3D machine learning enabled cell imaging. Kranda previously served as one of original board members for the Allen Institute for Brain Science as well as Managing Director of Vulcan Capital, Microsoft co-founder Paul Allen's life science venture capital group. Prior positions in the industry include President of Immunex, CEO of Oxford GlycoSciences, and Director and Audit Committee Chairman for PTC Therapeutics.

About LifeSprout, Inc.

LifeSprout, Inc. is a privately held company developing revolutionary products for aesthetic and regenerative medicine. LifeSprout's proprietary Regenerative Matrix platform comprises biomimetic, biocompatible materials engineered to look and feel like natural tissue. The first product from this platform ? Luminatm ? is a next-generation aesthetic dermal filler that combines the proven safety of hyaluronic acid with bio stimulatory effects. LifeSprout is turning this technology into a suite of products for the millions of patients with tissue losses from aging, cancer, and orphan diseases. The Company is supported by Redmile Group, Triskelion Investments, Catalio Capital Management, Emerald Development Managers, and other leading institutional and family office firms.

These press releases may also interest you

at 11:30
The "Chimeric Antigen Receptor (CAR) T-Cell Therapy - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor (CAR) T-Cell Therapy epidemiology division provides insights about...

at 11:30
The "Allogenic iNKT cell therapy - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Allogenic iNKT cell therapy epidemiology division provides insights about historical and current patient pool and...

at 11:30
The French authorities validate the start of the therapeutic trial to evaluate the safety of the ExOlin® device for patients suffering from poorly controlled type 1 diabetes with severe glycaemic fluctuations and prone to severe hypoglycaemia....

at 11:20
The "Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) epidemiology division provides...

at 11:17
Researchers from Oregon Health & Science University found that a clinician-focused, COVID-19 support program with a chat box feature not only provided primary care medical staff with timely clinical resources and care guidance, but it also offered...

at 11:11
CSS Health, a leading provider of Medication Therapy Management Software and Services, today announced it's Payer Services unit (formerly CSS) has earned Certified status for information security by HITRUST....

News published on 18 november 2021 at 09:10 and distributed by: